Andrew Wei
安德鲁·韦
MBBS, PhD, FRACP, FRCPA
Professor and Head of Haematology血液科教授及主任
👥Biography 个人简介
Andrew Wei is Australia's foremost AML researcher and a global leader in BCL-2 inhibition and venetoclax-based regimens. He co-led the pivotal VIALE-A trial and has advanced MRD-guided therapy and novel combination strategies in AML.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
VIALE-A Trial Leadership
Co-led the international VIALE-A phase III trial demonstrating venetoclax plus azacitidine nearly doubled overall survival versus azacitidine alone in treatment-naive unfit AML patients.
MRD in AML
Advanced multiparameter flow cytometry and molecular MRD assessment in AML, establishing MRD negativity as a key surrogate endpoint for durable remission in venetoclax-based trials.
Representative Works 代表性著作
Venetoclax plus Azacitidine versus Azacitidine in Untreated AML (VIALE-A)
New England Journal of Medicine (2020)
Landmark trial establishing the venetoclax–azacitidine combination as a new global standard for older or unfit AML patients, with improved OS and CR rates.
Molecular Minimal Residual Disease and the Kinetics of BCL-2 Inhibition in AML
Blood (2021)
Demonstrated the prognostic relevance of MRD clearance with venetoclax-based therapy, informing MRD-guided treatment strategies.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 安德鲁·韦 的研究动态
Follow Andrew Wei's research updates
留下邮箱，当我们发布与 Andrew Wei（Alfred Hospital / Monash University）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment